Mitigation of indomethacin-induced gastric mucosal lesions by a potent specific type V phosphodiesterase inhibitor  

作　　者：Kemal Karakaya Volkan Hanci Sibel Bektas Murat Can Hamdi B Ucan Ali Ugur Emre Oge Tasc1lar Is1l Ozkocak Turan Mustafa Comert Oktay Irkorucu Guldeniz Karadeniz Cakmak 

机构地区：[1]Department of General Surgery,Zonguldak Karaelmas University,Medical Faculty [2]Department of Anesthe-siology,Zonguldak Karaelmas University,Medical Faculty [3]Department of Pathology,Zonguldak Karaelmas University,Medical Faculty [4]Department of Biochemistry,Zonguldak Karaelmas University,Medical Faculty

出　　处：《World Journal of Gastroenterology》2009年第40期5091-5096,共6页世界胃肠病学杂志（英文版）

摘　　要：AIM: To investigate the gastroprotective effect of vardenafil against indomethacin-induced gastric damage. METHODS: Forty-eight female Wistar albino rats were randomly divided into 6 groups. Group 1 received saline only. Group 2 (indomethacin) received indomethacin. Rats in group 3 and 4 were pretreated with different doses of famotidine. Group 5 and 6 were pretreated with different doses of vardenafil. Rats in groups 3 to 6 received 25 mg/kg indomethacin 30 min after pretreatment. The animals were sacrificed 6 h later and their stomachs were opened. Gastric lesions were counted and measured. The stomach of each animal was divided in two parts for histopathological examinations and nitric oxide (NO) and malondialdehyde (MDA) assays, respectively. RESULTS: There were no gastric mucosal lesion in the saline group but all rats in the indomethacin group had gastric mucosal ulcerations (ulcer count; 6.25 ± 3.49, and mean ulcer area; 21.00 ± 12.35). Ulcer counts werediminished with famotidine 5 mg/kg (4.12 ± 2.47, P > 0.05), 20 mg/kg (2.37 ± 4.43, P < 0.05), vardenaf il 2 mg/kg (4.37 ± 3.06), and vardenafil 10 mg/kg (1.25 ± 1.38, P < 0.05) compared to the indomethacin group. Gastric mucosal lesion areas were diminished with famotidine 5 mg/kg (8.62 ± 2.97, P < 0.001), famotidine 20 mg/kg (0.94 ± 2.06, P < 0.001), vardenafil 2 mg/kg (6.62 ± 5.87, P < 0.001), and vardenafil 10 mg/kg (0.75 ± 0.88, P < 0.001) compared to the indomethacin group. MDA levels were signif icantly higher in indometh-acin group (28.48 ± 14.51), compared to the famotidine 5 mg/kg (6,21 ± 1.88, P < 0.05), famotidine 20 mg/kg (5.88 ± 1.60. P < 0.05), vardenaf il 2 mg/kg (15.87 ± 3.93, P < 0.05), and vardenafil 10 mg/kg (10.97 ± 4.50, P < 0.05). NO concentration in gastric tissues of the fa-motidine groups were significantly increased (P < 0.05), but the NO increases in the vardenafil groups were not statistically significant. Histopathology revealed dimin-ished gastric damage for pretreatment groups compared to the indomethacin group AIM： To investigate the gastroprotective effect of vardenafil against indomethacin-induced gastric damage. METHODS： Forty-eight female Wistar albino rats were randomly divided into 6 groups. Group 1 received saline only. Group 2 （indomethacin） received indomethacin. Rats in group 3 and 4 were pretreated with different doses of famotidine, Group 5 and 6 were pretreated with different doses of vardenafil. Rats in groups 3 to 6 received 25 mg/kg indomethacin 30 min after pretreatment. The animals were sacrificed 6 h later and their stomachs were opened. Gastric lesions were counted and measured. The stomach of each animal was divided in two parts for histopathological examinations and nitric oxide （NO） and malondialdehyde （MDA） assays, respectively.RESULTS： There were no gastric mucosal lesion in the saline group but all rats in the indomethacin group had gastric mucosal ulcerations （ulcer count; 6.25 ± 3.49, and mean ulcer area; 21.00 ± 12.35）. Ulcer counts were diminished with famotidine 5 mg/kg （4.12 ± 2.47, P 〉 0.05）, 20 mg/kg （2.37 ± 4.43, P 〈 0.05）, vardenafil 2 mg/kg （4.37 ± 3.06）, and vardenafil 10 mgkg （1.25 ± 1.38, P 〈 0.05） compared to the indomethacin group. Gastric mucosal lesion areas were diminished with famotidine 5 mg/kg （8.62 ± 2.97, P 〈 0.001）, famotidine 20 mg/kg （0.94 ± 2.06, P 〈 0.001）, vardenafil 2 mg/kg （6.62 ± 5.87, P 〈 0.001）, and vardenafil 10 mg/kg （0.75 ± 0.88, P 〈 0.001） compared to the indomethacin group. MDA levels were significantly higher in indomethacin group （28.48 ± 14.51）, compared to the famotidine 5 mg/kg （6,21 ± 1.88, P 〈 0.05）, famotidine 20 mg/kg （5.88 ± 1.60. P 〈 0.05）, vardenafil 2 mg/kg （15.87 ± 3.93, P 〈 0.05）, and vardenafil 10 mg/kg （10.97 ± 4.50, P 〈 0.05）. NO concentration in gastric tissues of the famotidine groups （were significantly increased （P 〈 0.05）, but the NO increases in the vardenafil groups were not statistically significant. Histopathol

关 键 词：VARDENAFIL Gastric ulceration INDOMETHACIN GASTROPROTECTION Rats 

分 类 号：R573[医药卫生—消化系统]